EXOZYMES INC. Cash Flow Statement
EXOZ|1 years of annual SEC 10-K data (FY2024-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid. All figures from audited SEC 10-K filings.
EXOZYMES INC. used $1M in operating cash flow and negative free cash flow of $1M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 |
|---|---|
| Net Income | -$2.0M |
| Depreciation & Amortization | $196.9K |
| Operating Cash Flow | -$1.2M |
| Capital Expenditures | $288.7K |
| Free Cash Flow | -$1.5M |
| FCF Margin | -2097.3% |